KISS1R: Phase 1 Wet-Lab — KP-10 Reference + ncAA Leads C1-01, C1-02

Kiss1r: Phase 1 Wet-lab — Kp-10 Reference + Ncaa Leads C1-01, C1-02

C1-01 (D-Tyr¹/Arg(Me)⁹) and C1-02 (Ac/D-Tyr¹/Thr⁵/azaGly⁷/Arg(Me)⁹) are ncAA-modified kisspeptin decapeptide agonists of KISS1R (GPR54) selected from the Generation 1 computational pipeline (PRODIGY-estimated Kd 0.64 nM and ~140 pM respectively). This Phase 1 wet-lab compares both leads against the natural-AA reference KP-10 (YNWNSFGLRF-NH2) at Adaptyv (BLI + NPFFR1/NPFFR2 selectivity counter-screens), with cAMP HTRF at Ginkgo on top binders and plasma-stability LC-MS on leads.

Description

Team

0x6a41b…b2173

Owner

Project Score

Updated Sep 29, 2026

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Project Progress

All updates

All categories

Timeline

Kiss1r: Phase 1 Wet-lab — Kp-10 Reference + Ncaa Leads C1-01, C1-02

Description

Team

0x6a41b…b2173

Owner

Project Score

Updated Sep 29, 2026

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Project Progress

All updates

All categories

Timeline

Rationale

The project is entirely in the computational discovery phase with no wet-lab experimental work conducted. All reported data — binding affinities, stability assessments, selectivity predictions, solubility, and immunogenicity — are derived exclusively from in silico computational tools (Boltz2, PRODIGY, OpenMM MD simulations, CamSol, MHCflurry, etc.). The first physical experiments (BLI binding at Adaptyv Bio, cAMP HTRF assays at Ginkgo Bioworks) are planned for Q2 2026 but have not yet been initiated. Per the decision tree, the absence of ANY experimental laboratory work classifies this project as TRL 1.

Assessment

Low Confidence

RecommendationPROMOTE

Total Score4.45

Overall Assessment

This KISS1R agonist peptide program scores 4.45/5.00 at TRL 1, reflecting a very strong early-stage discovery project. The dominant contributor is Therapeutic Relevance (weighted score 3.0/3.0), which earns a perfect 5/5 due to the exceptionally well-validated target biology: KISS1R loss-of-function mutations are directly causative of IHH, two independent clinical programs (MVT-602, TAK-683) validate the target, and the computational pipeline is rigorous with a 9-gate framework built on a high-resolution cryo-EM structure. The IP position is strong (4/5, weighted 1.0/1.25), with novel modification combinations and emerging selectivity engineering strategies, though tempered by existing prior art in the kisspeptin analogue space. Therapeutic Optionality is moderate (3/5, weighted 0.45/0.75), as the mechanism is primarily focused on reproductive endocrinology with some extension potential but limited broad diversification. Key risks at this stage include: (1) all data are purely computational with no wet-lab validation yet; (2) the NPFFR1/NPFFR2 selectivity challenge is a real pharmacological concern inherent to the RF-amide scaffold; and (3) the competitive landscape includes established pharma players. The program's systematic approach, clear decision criteria, and designed experimental validation plan position it well for TRL advancement pending G9 wet-lab results.

Weighted Score

Therapeutic Relevance

The mechanism is highly scientifically plausible and targets a well-validated, biologically relevant disease pathway. KISS1R (GPR54) is the obligate receptor for kisspeptin peptides that drive GnRH pulsatility via the HPG axis, and loss-of-function mutations in KISS1/KISS1R are directly causative of idiopathic hypogonadotropic hypogonadism (IHH). Clinical precedents (MVT-602 Phase I/II, TAK-683) independently validate KISS1R as a druggable target. The computational pipeline is built on a high-resolution cryo-EM structure (PDB 8XGO, 2.68 Å), and both lead candidates show strong predicted binding (Kd 0.64 nM and ~140 pM) with mechanistically rational scaffold modifications (D-Tyr1, Arg(Me)9, azaGly7) that address known liabilities of the native KP-10 peptide. The Gαq/11-coupled signaling cascade (PLC→IP3/DAG→Ca²⁺/ERK1/2) is well-characterized. The only caveat is that all data remain computational—no wet-lab confirmation yet—but at TRL 1 the scientific plausibility and target validation are exceptionally strong.

Therapeutic Optionality

The concept has moderate therapeutic optionality. The primary indication (IHH) is well-defined but relatively narrow (1 in 4,000–10,000 individuals). The kisspeptin/KISS1R axis has potential relevance beyond IHH to broader fertility disorders (as demonstrated by MVT-602's clinical work in follicular development), and kisspeptin biology touches on puberty, metabolic regulation, and potentially oncology (KISS1 as a metastasis suppressor gene). The library of 10 candidates with diverse modification strategies (PEGylation, cyclic lactam, bivalent scaffolds, fluorinated aromatics) and the Generation 2/3 design pivot show flexibility in the concept. However, the core mechanism—agonism of a single GPCR in the HPG axis—is inherently focused on reproductive endocrinology, limiting broad therapeutic area diversification. The peptide modality also constrains delivery to injectable routes, somewhat limiting optionality.

Intellectual Property

The candidates incorporate novel combinations of non-natural amino acid modifications (D-Tyr1, Arg(Me)9, azaGly7, Thr5 substitution, N-Ac capping) that are distinct from known clinical compounds (MVT-602, TAK-683). The specific peptide sequences C1-01 and C1-02 with their defined modification patterns appear patentable as novel chemical entities. The Generation 2 innovations—Trp10 substitution for NPFFR selectivity and Cit9 charge elimination—represent additional novel IP angles. The structural rationale for selectivity (Ala287 vs Asp at BW 6.59) could support method-of-use and composition-of-matter claims. However, the kisspeptin analogue space has prior art from Myovant/Sumitovant (MVT-602), Takeda (TAK-683), and academic groups (Nishizawa 2012), and individual modifications like D-amino acid substitutions and Arg methylation are known in the peptide engineering literature. The RF-amide pharmacophore is a shared structural feature that constrains the design space. Score of 4 reflects strong but not uncontested novelty, with some prior art risk in the broader kisspeptin analogue field.